drugset / Trial / NCT00388609

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

NCT00388609 ↗

Phase 2 Terminated 705 enrolled Bristol-Myers Squibb Solvay Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: * overweight with high blood pressure or high cholesterol or * obese The safety of this treatment will also be studied

Timeline

Start
2006-11
Primary completion
2007-09
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ibipinabant Small molecule 50 mg —

Indications